Background
Methods
Study Design
Patient No. | Age (yr.) | Race | Serum PSA at Initial Diagnosis (ng/ml) | Gleason Score at Initial Diagnosis | Clinical Stage at Initial Diagnosis | Initial Treatment | Length of F/U months |
---|---|---|---|---|---|---|---|
1 | 62 | White | UNK | 3+4 = 7 | T3aNxMx | RP | 12 |
2 | 67 | White | 4.8 | 3+3 = 6 | T2xNxMx | Brachy/EBRT/ADT | 12 |
3 | 67 | White | UNK | 3+3 = 6 | T2xNxMx | RP | 12 |
4 | 78 | White | 4.7 | 3+4 = 7 | T2aNxMx | Brachy/EBRT/ADT | 6, started ADT |
5 | 77 | African American | 14.08 | UNK | T3aNxMx | RP/EBRT | 12 |
6 | 75 | White | 8.28 | 4+5 = 9 | T2cNxMx | ADT/RP | 12 |
7 | 69 | White | 10.36 | 3+3 = 6 | T1cNxMx | EBRT | 12 |
8 | 71 | White | UNK | UNK | UNK | RP/Salvage EBRT | 12 |
9 | 75 | White | UNK | 4+4 = 8 | T2bNxMx | EBRT/ADT | 12 |
10 | 77 | White | 8.1 | 4+5 = 9 | T3bNxMx | RP | 3, started ADT |
11* | 79 | White | UNK | 2+3 = 5 | T1cNxMx | EBRT | 9, withdrew due to side effects |
12 | 68 | White | UNK | 4+4 = 8 | T2aNxMx | RP/Adjuvant EBRT | 6, started ADT |
13 | 76 | African American | 11.13 | 3+3 = 6 | T2aNxMx | EBRT | 12 |
14 | 79 | White | 4.0 | 3+4 = 7 | T1cNxMx | RP/Adjuvant EBRT | 12 |
15 | 73 | White | 10 | 3+2 = 5 | T1cNxMx | EBRT | 12 |
16 | 60 | White | 9.2 | 3+4 = 7 | T1cNxMx | RP/Adjuvant EBRT | 12 |
17 | 63 | White | 17.3 | 4+3 = 7 | T1cNxMx | EBRT | 12 |
18 | 70 | White | 9.8 | 3+3 = 6 | T2xNxMx | RP/salvage EBRT | 12 |
19* | 76 | African American | 4.1 | 3+4 = 7 | T2bNxMx | RP | 6, lost to F/U |
20 | 77 | White | 8.7 | UNK | T2aNxMx | EBRT | 6, lost to F/U |
Median | 73 | --- | 9.2 | 7 | --- | --- | 12 |
Isoflavone Analysis
Genomic DNA Isolation & Evaluation of AR CAG Polymorphisms
Statistical analysis
Pt No. | PSA at entry (ng/ml) | PSA at 12 months (ng/ml) | Free PSA at entry (ng/ml) | Free PSA at 12 months (ng/ml) | Testosterone at entry (ng/ml) | Testosterone at 12 months (ng/ml) | Free Testosterone at entry (ng/ml) | Free Testosterone at 12 months (ng/ml) | Cholesterol at entry (mg/dl) | Cholesterol at 12 months (mg/dl) |
---|---|---|---|---|---|---|---|---|---|---|
1 | 0.57 | 1.93 | 0.10 | 0.381 | 493 | 468 | N/A | 10.1 | 195 | 207 |
2 | 0.50 | 0.35 | 0.08 | 0.007 | 331 | 382 | 46.7 | 8.5 | 148 | 134 |
3 | 1.76 | 1.62 | N/A | N/A | 259 | 263 | 11.9 | N/A | 229 | N/A |
4 | 1.17 | N/A | 0.11 | N/A | 508 | N/A | 9.3 | N/A | 109 | N/A |
5 | 6.87 | 11.23 | N/A | 1.690 | 324 | 299 | N/A | 5.7 | 203 | 173 |
6 | 5.94 | 13.41 | 0.83 | 2.250 | N/A | 418 | N/A | 9.7 | 140 | 134 |
7 | 1.18 | 1.73 | N/A | 0.280 | 264 | 118 | N/A | 5.5 | 162 | 141 |
8 | 0.67 | N/A | 0.08 | N/A | 264 | N/A | 10.2 | N/A | 167 | N/A |
9 | 0.15 | 0.12 | 0.01 | N/A | 68 | 68 | 3.4 | N/A | 260 | 197 |
10 | 0.4 | N/A | N/A | N/A | 360 | N/A | N/A | N/A | N/A | N/A |
11 | 18.86 | N/A | N/A | N/A | 137 | N/A | 4.6 | N/A | 199 | N/A |
12 | 11.21 | N/A | 1.49 | N/A | 204 | N/A | N/A | N/A | 134 | N/A |
13 | 0.74 | 0.67 | 0.07 | N/A | 565 | N/A | 15.6 | N/A | 319 | N/A |
14 | 3.49 | 3.90 | 0.22 | 3.902 | 280 | 265 | 10.4 | 9.7 | 151 | 145 |
15 | 1.36 | 1.59 | N/A | N/A | 521 | 487 | 19.3 | N/A | 255 | 235 |
16 | 0.50 | 0.50 | N/A | 0.020 | N/A | 281 | N/A | 12.0 | N/A | 200 |
17 | 2.67 | 5.15 | 0.15 | 0.290 | 287 | 382 | 9.8 | 0.9 | 180 | 170 |
18 | 0.59 | 1.10 | N/A | 0.100 | 333 | 317 | 4.0 | 47.6 | 147 | 163 |
19 | 1.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
20 | 0.79 | 1.05 | N/A | N/A | 299 | N/A | 10.5 | N/A | 116 | 171 |
Median | 1.11 | 1.61 | 0.11 | 0.19 | 299 | 308 | 10.3 | 9.7 | 167 | 171 |
P value | 0.081 | 0.285 | 0.064 | 0.031 | 0.806 |
Results
Subjects' characteristics
PSA level – Reduction
PSA level – Comparison of Slopes
PSA doubling time
Other chemistries
Isoflavone Level and AR Molecular Weight
Patient No. | Total Genistein (μg/ml) | Total Daidzein (μg/ml) | Total Equol (μg/ml) | Androgen Receptor CAG repeat |
---|---|---|---|---|
1 | 0.709 | 0.735 | 0.115 | 21 |
2 | 1.284 | 0.660 | 0.063 | 26 |
3 | 0.189 | 0.468 | 0.331 | 21 |
4 | 0.555 | 0.409 | 0.306 | 21 |
5 | 0.102 | 0.572 | 0.523 | 13 |
6 | 0.739 | 0.468 | 0.039 | 16 |
7 | 2.071 | 0.602 | 0.329 | 20 |
8 | N/A | N/A | N/A | 30 |
9 | 0.022 | 0.014 | 0.020 | 21 |
10 | N/A | N/A | N/A | 24 |
11 | 0.023 | 0.568 | <0.001 | 16 |
12 | 0.186 | 0.063 | 0.061 | 16 |
13 | <0.002 | 0.005 | 0.048 | 19 |
14 | 0.058 | 0.192 | 0.050 | 21 |
15 | 1.049 | 0.580 | 0.188 | 21 |
16 | 0.492 | 0.170 | 0.062 | 17 |
17 | 1.989 | 0.817 | 0.492 | 24 |
18 | <0.002 | 0.021 | 0.119 | 19 |
19 | N/A | N/A | N/A | N/A |
20 | N/A | N/A | N/A | N/A |
Median | 0.524 | 0.468 | 0.115 | --- |